Payne NL, Pang SHM, Freeman AJ, Ozkocak DC, Limar JW, Wallis G, Zheng D, Mendonca S, O’Reilly LA, Gray DHD, Poon IKH, Heng TSP. Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis. Cell Death Discovery. 2025;11(1):10.1038/s41420-025-02412-0
Luo M-X, Tan T, Trussart M, Poch A, Nguyen TMH, Speed TP, Hicks DG, Bandala-Sanchez E, Peng H, Chappaz S, Slade C, Utzschneider DT, Koldej RM, Ritchie D, Strasser A, Thijssen R, Ritchie ME, Tam CS, Lindeman GJ, Huang DCS, Lew TE, Anderson MA, Roberts AW, Teh CE, Gray DHD. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia. Blood. 2024;144(26):10.1182/blood.2024024341
Kousa AI, Jahn L, Zhao K, Flores AE, Acenas D, Lederer E, Argyropoulos KV, Lemarquis AL, Granadier D, Cooper K, D’Andrea M, Sheridan JM, Tsai J, Sikkema L, Lazrak A, Nichols K, Lee N, Ghale R, Malard F, Andrlova H, Velardi E, Youssef S, Burgos da Silva M, Docampo M, Sharma R, Mazutis L, Wimmer VC, Rogers KL, DeWolf S, Gipson B, Gomes ALC, Setty M, Pe’er D, Hale L, Manley NR, Gray DHD, van den Brink MRM, Dudakov JA. Age-related epithelial defects limit thymic function and regeneration. Nature Immunology. 2024;25(9):10.1038/s41590-024-01915-9
Biemond M, Vremec D, Gray DH, Hodgkin PD, Heinzel S. Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1. Immunology and Cell Biology. 2024;102(2):10.1111/imcb.12714
Joyce R, Pascual R, Heitink L, Capaldo BD, Vaillant F, Christie M, Tsai M, Surgenor E, Anttila CJA, Rajasekhar P, Jackling FC, Trussart M, Milevskiy MJG, Song X, Li M, Teh CE, Gray DHD, Smyth GK, Chen Y, Lindeman GJ, Visvader JE. Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers. Nature Cell Biology. 2024;26(1):10.1038/s41556-023-01315-5
Chua CC, Anstee N, Flensburg C, Teh C, Ivey A, Amin N, Thijssen R, Bohlander SK, Kakadia PM, Xu Z, Fong CY, Ting S, Loo S, Tiong IS, Gray D, Fleming S, Davidson N, Roberts AW, Majewski I, Wei AH, Brown FC. Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations. Blood. 2023;142(Supplement 1):10.1182/blood-2023-185321
Tiong IS, Nguyen T, Teh C, Chua CC, Ftouni S, Lew TE, Brown FC, Moujalled D, Muttiah C, Gray D, Anderson MA, Thompson PA, Tam CS, Seymour JF, Dawson S-J, Wei AH, Lindeman G, Blombery P. BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms. Blood. 2023;142(Supplement 1):10.1182/blood-2023-180386
Xu C, Li S, Fulford TS, Christo SN, Mackay LK, Gray DH, Uldrich AP, Pellicci DG, I Godfrey D, Koay H-F. Expansion of MAIT cells in the combined absence of NKT and γδ-T cells. Mucosal Immunology. 2023;16(4):10.1016/j.mucimm.2023.05.003
Teh CE, Peng H, Luo M, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown FC, Ritchie ME, Wei AH, Roberts AW, Bryant VL, Anderson MA, Lindeman GJ, Huang DCS, Thijssen R, Gray DHD. Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells. Blood Advances. 2023;7(12):10.1182/bloodadvances.2022008221
Abdulla HD, Alserihi R, Flensburg C, Abeysekera W, Luo M-X, Gray DHD, Liu X, Smyth GK, Alexander WS, Majewski IJ, McCormack MP. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition. Journal of Experimental Medicine. 2023;220(6):10.1084/jem.20212383
